Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLASSIFY: Clarithromycin to Prevent Secondary Infections in Sepsis After Community-Acquired Pneumonia
2025-525058-20-00Phase 3Authorised
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in community-acquired pneumonia (CAP), sepsis, immunologic paralysis and 1 more comparing Klaricid plus standard-of-care antibiotics with Placebo plus standard-of-care antibiotics (2 arms). Primary endpoint: Composite incidence of new or worsened infection. Planned start Jun 2026; status: authorised.
02
Drugs
clarithromycin
03
Conditions
community-acquired pneumonia (CAP)sepsisimmunologic paralysissuperinfection
Beyond the preview
Go deeper on 2025-525058-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525058-20-00.